Open an account

Progyny

PGNY · NASDAQ

$28.58+$0.74 (+2.66%)TodayMarket closed ·
Prev close $27.84

About PGNY

Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 856 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Employees
856
Headquarters
New York City, New York
Listed
Oct 25, 2019
Sector
Health Care
Industry
Health Care Providers & Services
Website
progyny.com

PGNY key statistics

Market cap
2.14B
Price-earnings ratio
30.26
Dividend yield
—
Average volume
1.13M
Volume
926.54K
Open price
$28.03
High today
$28.95
Low today
$28.03
52 Week high
$33.07
52 Week low
$16.10

Progyny (PGNY) at a glance

As of Oct 20, 2026, Progyny (PGNY) shares are priced at $28.58, giving the company a market cap of 2.14B and a price-to-earnings ratio of 30.26.

Today the stock has traded between $28.03 and $28.95. The current price is 2.0% above the day's low and 1.3% below its high.

Volume so far is 926.54K shares, in line with the average of 1.13M shares a day.

Over the past year Progyny has ranged from $16.10 to $33.07, and now sits 74% of the way up that range.

Progyny met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.34 per share against an estimate of $0.3417.

The average analyst price target is $35.51, 24.3% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 10 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 14 analystsAvg $35.51
Low
$30.30
Now
$28.58
High
$42.00

PGNY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 14.6% on average.

  1. Q3 FY24: reported $0.11 per share against an estimate of $0.136
  2. Q4 FY24: reported $0.12 per share against an estimate of $0.1043
  3. Q1 FY25: reported $0.17 per share against an estimate of $0.1927
  4. Q2 FY25: reported $0.19 per share against an estimate of $0.1658
  5. Q3 FY25: reported $0.15 per share against an estimate of $0.1313
  6. Q4 FY25: reported $0.14 per share against an estimate of $0.1479
  7. Q1 FY26: reported $0.29 per share against an estimate of $0.3049
  8. Q2 FY26: reported $0.34 per share against an estimate of $0.3417

PGNY news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Earnings Scheduled For November 6, 2025

  • Press releaseBusiness Wire

    Transcarent Experience Store Expansion: More Options for Women's Health

Similar companies

Companies in the same industry as Progyny

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.